Differential gene expression in melanocytic nevi with the V600E BRAF mutation

We studied gene expression in 18 melanocytic nevi with and four nevi without the V600E mutation in the BRAF gene using HG‐U133A 2.0 microarray with 22,277 transcripts. Data analysis revealed 92 genes up‐regulated and 105 genes down‐regulated in nevi with the mutation compared to nevi without mutation. Pathway analysis showed that differentially regulated genes mapped to 10 genetic networks. The major network included genes involved in cell death, cell cycle, and cellular growth and proliferation. Up‐regulated genes in nevi with the mutation included CDKN2A, CDKN1C, and MITF; whereas down‐regulated genes included those involved in apoptotic and other pathways. Principal component analysis identified 22 probe sets (20 genes) that caused separate segregation of nevi with and without mutations. In conclusion, our data showed differences in gene expression between nevi with and without the V600E BRAF mutation. Moreover, nevi with mutations showed over‐expression of genes involved in melanocytic senescence and cell cycle inhibition. © 2007 Wiley‐Liss, Inc.

[1]  C. Mackay,et al.  Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses , 2007, Nature Reviews Drug Discovery.

[2]  A. Eggermont,et al.  Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.

[3]  Yixin Wang,et al.  Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions , 2005, Clinical Cancer Research.

[4]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[5]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[6]  D. Schadendorf,et al.  Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. , 2005, Carcinogenesis.

[7]  A. Trumpp,et al.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. , 2005, Cancer research.

[8]  B. Ljung,et al.  The gene expression signatures of melanoma progression , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[10]  R. Delston,et al.  MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A , 2005, The Journal of cell biology.

[11]  H. Kittler,et al.  BRAF kinase gene V599E mutation in growing melanocytic lesions. , 2004, The Journal of investigative dermatology.

[12]  M. Pierotti,et al.  BRAF alterations are associated with complex mutational profiles in malignant melanoma , 2004, Oncogene.

[13]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[14]  K. Hemminki,et al.  BRAF mutations are common somatic events in melanocytic nevi. , 2004, The Journal of investigative dermatology.

[15]  K. Hemminki,et al.  Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 , 2003, Oncogene.

[16]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Motoi,et al.  Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. , 2003, The American journal of pathology.

[18]  G. Peters,et al.  p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. , 2003, Journal of the National Cancer Institute.

[19]  D. Bennett.  Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.

[20]  K. Smalley,et al.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.

[21]  D. Bennett,et al.  Molecular regulation of melanocyte senescence. , 2002, Pigment cell research.

[22]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[23]  A. Ashworth,et al.  MAP kinase phosphatases , 2002, Genome Biology.

[24]  L. Chin,et al.  p16(Ink4a) in melanocyte senescence and differentiation. , 2002, Journal of the National Cancer Institute.

[25]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[26]  A. Elefanty,et al.  Human acquired naevi are clonal , 1998, Melanoma research.

[27]  P. Uribe,et al.  Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. , 2006, The Journal of investigative dermatology.

[28]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.